CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
28 hedge funds and large institutions have $12.8M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
5% less capital invested
Capital invested by funds: $13.5M → $12.8M (-$657K)
Holders
28
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$2.26M | |
| 2 | +$768K | |
| 3 | +$332K | |
| 4 |
PCM
Prelude Capital Management
New York
|
+$291K |
| 5 |
CIA
Choate Investment Advisors
Boston,
Massachusetts
|
+$248K |
Top Sellers
| 1 | -$1.8M | |
| 2 | -$682K | |
| 3 | -$373K | |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$207K |
| 5 |
RPG
Risk Paradigm Group
Austin,
Texas
|
-$77K |